Andrew D J Pearson Selected Research

Andrew D J Pearson Research Topics

Disease

48	Neoplasms (Cancer) 05/2024 - 10/2002
45	Neuroblastoma 01/2024 - 01/2002
5	Glioma (Gliomas) 01/2017 - 01/2009
4	Glioblastoma (Glioblastoma Multiforme) 01/2017 - 09/2009
4	Medulloblastoma 01/2011 - 10/2002
2	Neoplasm Metastasis (Metastasis) 01/2021 - 03/2009
2	Infections 12/2018 - 01/2017
2	Fatigue 05/2017 - 12/2016
2	Thrombocytopenia (Thrombopenia) 05/2017 - 12/2016
2	Stomatitis 01/2017 - 12/2016
2	Ewing Sarcoma (Sarcoma, Ewing) 01/2016 - 10/2003
1	Disease Progression 01/2021
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020
1	Hemorrhage 01/2019
1	Pulmonary Hypertension 12/2018
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 12/2018
1	Capillary Leak Syndrome 12/2018
1	Heart Failure 12/2018
1	Fever (Fevers) 12/2018
1	Mycoses (Diseases, Fungus) 12/2018
1	Pain (Aches) 12/2018
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 12/2018
1	Hypersensitivity (Allergy) 12/2018
1	Bone Marrow Diseases (Bone Marrow Disease) 01/2018
1	Retinoblastoma (Glioblastoma, Retinal) 05/2017
1	Rhabdoid Tumor (Rhabdoid Tumors) 05/2017
1	Hypertriglyceridemia 12/2016
1	Hypercholesterolemia 12/2016

Drug/Important Bio-Agent (IBA)

10	Biomarkers (Surrogate Marker)IBA 05/2024 - 01/2013
7	DNA (Deoxyribonucleic Acid)IBA 01/2014 - 10/2002
6	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2004
5	Temozolomide (Temodar)FDA LinkGeneric 01/2024 - 11/2010
4	Topotecan (Hycamtin)FDA LinkGeneric 01/2024 - 01/2017
4	Vincristine (Oncovin)FDA LinkGeneric 10/2021 - 01/2017
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2021 - 01/2004
3	CrizotinibIBA 11/2021 - 07/2012
3	Carboplatin (JM8)FDA LinkGeneric 10/2021 - 05/2010
3	dinutuximabIBA 10/2021 - 12/2018
3	Etoposide (VP 16)FDA LinkGeneric 10/2021 - 05/2010
3	Melphalan (Alkeran)FDA LinkGeneric 10/2021 - 07/2013
3	Ferritins (Ferritin)IBA 01/2020 - 10/2014
3	Phosphotransferases (Kinase)IBA 01/2020 - 09/2009
3	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2018 - 01/2017
3	3-Iodobenzylguanidine (Iobenguane)IBA 01/2018 - 08/2003
3	MethyltransferasesIBA 11/2010 - 10/2002
3	Tumor Suppressor Protein p14ARF (p14ARF)IBA 02/2010 - 05/2004
3	Tretinoin (Retinoic Acid)FDA LinkGeneric 11/2007 - 01/2002
3	RetinoidsIBA 01/2002 - 01/2002
2	Angiogenesis InhibitorsIBA 01/2024 - 01/2013
2	Cisplatin (Platino)FDA LinkGeneric 10/2021 - 01/2017
2	Busulfan (Busulfex)FDA Link 10/2021 - 01/2017
2	Interleukin-2 (IL2)IBA 10/2021 - 12/2018
2	Isotretinoin (Accutane)FDA LinkGeneric 10/2021 - 01/2013
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2021 - 10/2014
2	Aurora Kinase AIBA 01/2020 - 01/2015
2	cediranib (AZD2171)IBA 01/2019 - 01/2013
2	Antineoplastic Agents (Antineoplastics)IBA 11/2017 - 01/2011
2	Choline (Choline Chloride)IBA 01/2017 - 01/2014
2	PI103IBA 01/2017 - 01/2014
2	Lactic Acid (Lactate)FDA LinkGeneric 01/2017 - 01/2014
2	Phosphorylcholine (Phosphocholine)IBA 01/2017 - 01/2014
2	Oncogene Proteins (Oncogene Protein)IBA 04/2016 - 11/2013
2	1- cyclopropyl- 3- (3- (5- morpholin- 4- ylmethyl- 1H- benzoimidazol- 2- yl)- 1H- pyrazol- 4- yl)ureaIBA 01/2015 - 09/2011
2	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2014 - 11/2010
2	Anti-Bacterial Agents (Antibiotics)IBA 03/2008 - 08/2005
2	Dactinomycin (Actinomycin)FDA LinkGeneric 08/2005 - 10/2003
2	Decitabine FDA Link 05/2004 - 10/2002
2	Messenger RNA (mRNA)IBA 08/2003 - 01/2002
2	cellular retinoic acid binding protein IIIBA 01/2002 - 01/2002
2	Retinoid X Receptors (Retinoid X Receptor)IBA 01/2002 - 01/2002
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2024
1	Bevacizumab (Avastin)FDA Link 01/2024
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2023
1	Anaplastic Lymphoma KinaseIBA 11/2021
1	Biological FactorsIBA 01/2021
1	regorafenibIBA 01/2021
1	MLN 8237IBA 01/2020
1	AntigensIBA 01/2020
1	quizartinibIBA 01/2020
1	vistusertibIBA 01/2020
1	Immune Checkpoint InhibitorsIBA 01/2020
1	AntibodiesIBA 01/2020
1	dabrafenibIBA 12/2019
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2019
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/2018
1	Monoclonal AntibodiesIBA 12/2018
1	IodineIBA 01/2018
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 05/2017
1	Cyclin DIBA 05/2017
1	ribociclibIBA 05/2017
1	MTOR InhibitorsIBA 01/2017

Therapy/Procedure

32	Therapeutics 05/2024 - 07/2003
11	Drug Therapy (Chemotherapy) 01/2024 - 07/2003
8	Investigational Therapies (Experimental Therapy) 05/2024 - 01/2016
8	Immunotherapy 10/2021 - 01/2013
4	Induction Chemotherapy 01/2019 - 03/2008
3	Radiotherapy 10/2021 - 01/2014
3	Aftercare (After-Treatment) 12/2018 - 10/2002
2	Precision Medicine 01/2020 - 01/2019
1	Duration of Therapy 12/2019